Prof. Dale Sanders
After a successful career at the University of York, during which time he was awarded the Koerber European Science Prize and was elected as a Fellow of the Royal Society, Dale left his post as Head of the Biology Department in 2010 to become Director of the John Innes Centre, from whence Leaf Expression Systems emerged.
Dr. Steven Powell
Steven was CEO of KS Biomedix plc from 1999 until its acquisition by Xenova in 2003 and CEO of Plethora Solutions plc until 2011. He has been an adviser to Gilde Healthcare, a Dutch VC fund, for over 12 years and is adviser to the Pioneer Cancer Fund (UK) and Trustee of a medical research charity.
Chief Executive Officer
Simon has over thirty years of global international experience in life sciences, including his recent roles as CEO of Stratophase Ltd and Project Director for the design and build of the UK Government’s Cell and Gene Therapy Catapult commercial scale GMP Manufacturing Centre in Stevenage. He was appointed as CEO of Leaf Expression Systems in August 2018.
Dr Colin Miles
Dr Colin Miles is Head of the Strategy and team leader for the Industrial Biotechnology and Bioenergy sector at BBSRC. His current role is to lead a team in BBSRC to help increase the capacity and capability of the UK academic base in research, training and knowledge exchange activities in UK industrial biotechnology and bioenergy research.
Dr. Jan Chojecki
Jan is Managing Director of Plant Bioscience Limited. Prior to joining PBL in 1997, Jan spent 11 years with Zeneca plc. He has also served on the boards of several PBL spin-out companies, including Novacta Biosystems Ltd, Chameleon Biosurfaces Ltd, Procarta Bioscience Ltd, IDNA, Genetics Ltd and others. Between 2001 and 2007, Jan was Scientific Advisor to the Cambridge Gateway Fund.
Dr David Simpson
David co-founded Iksuda Therapeutics (formerly Glythera) in 2012, refocusing it into an Antibody Drug Conjugate development company underpinned by its proprietary technology platforms. Prior to Iksuda, David led Actavis’s biosimilar programmes (now Allergan) and started his industrial career developing expression systems with Cobra Biomanufacturing before moving to Eden Biodesign Ltd where he led its Process Development capabilities.